Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04463004 |
Recruitment Status :
Active, not recruiting
First Posted : July 9, 2020
Last Update Posted : February 17, 2021
|
Sponsor:
Virginia Commonwealth University
Collaborator:
Kiniksa Pharmaceuticals, Ltd.
Information provided by (Responsible Party):
Virginia Commonwealth University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | August 2021 |
Estimated Study Completion Date : | August 2021 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):